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INTRODUCTION
Lung cancer is the leading cause of cancer death worldwide, 
with a relative survival rate of about 25% in the 5 years follow-
ing the initial diagnosis.1 According to American Cancer Soci-
ety estimates, there will be 222500 new cases of lung cancer in 
the United States in 2017 and 155870 deaths from lung cancer.2 
Based on these data, various attempts have been made around 
the world to develop effective screening methods for the de-
tection of lung cancer still in the treatable stages, with CT-
based screening methods currently being widely applied.3-5 
However, a high false positive rate due to nonspecific lesions 
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using these methods requires the urgent development of new 
and efficient diagnostic methods.6 
The staging of non-small cell lung cancer (NSCLC) described 
by the tumor-node-metastasis system is a key process in mak-
ing prognoses and setting treatment modalities. Recently, en-
dobronchial ultrasound-guided-transbronchial needle aspirate 
(EBUS-TBNA) assay has been widely applied worldwide, as the 
detection of cancer cells in the thoracic lymph node (LN) has 
become a major issue not only in the determination of the can-
cer stage and in the selection of treatment modalities, but also 
in the initial diagnosis and selection of drugs at the time of re-
currence.7 
The EBUS-TBNA procedure shows high diagnostic yields 
when a core biopsy specimen is secured, although diagnosis 
rates are lowered if only a cytology specimen is secured due to 
the location of the LN or upon other problems during the pro-
cedure. In cases where only cytologic specimens are obtained 
during the EBUS-TBNA procedure, problems arise in obtaining 
accurate diagnostic results due to the limited number of neo-
plastic cells obtained, background interference, etc. Therefore, 
repeated and consumable procedures are required for a long 
time in the procedure to obtain sufficient core biopsy speci-
mens.8 The rapid on-site evaluation (ROSE) methods that have 
been developed to overcome some of these problems. How-
ever, despite these advantages, ROSE is not widely used be-
cause of certain limitations, such as its limited ability to reach 
confirmatory results, the fact that it evaluates only the useful-
ness of the sample, and a lack of equipment or manpower.9 
Aminoacyl-tRNA synthetases (ARSs) are a group of enzymes 
responsible for protein synthesis and are essential for cell sur-
vival and growth. They also have non-canonical functions re-
lated to various life phenomena in various type of cells.10 Among 
the ARSs, leucyl-tRNA synthetase, methionyl-tRNA synthetase 
(MRS), and glutamyl-prolyl tRNA synthetase interact with the 
proteins in the mTORC1, GCN2, CDK4, and vascular endo-
thelial growth factor receptor (VEGFR) signal pathways, which 
play critical roles in various cancers.11-13 Recently, overexpres-
sion of some ARSs have been connected to increased survival 
in certain cancer patients,14 and attempts to treat various can-
cers using ARS inhibitors have been ongoing.15 ARSs are ca-
nonically present in the cytoplasm, but are also secreted out-
side the cell under various signals. The multi-functionality and 
multi-localization of ARSs makes them useful biomarker can-
didates in various types of tissue specimens, as well as blood. 
MRS, one of the ARSs, is an important enzyme for the ini-
tiation of translation and plays an important role in tumor 
growth.16 MRS increases ribosomal RNA biogenesis in the nu-
cleolus and interacts with a variety of signaling molecules, 
such as mTORC1, GCN2, CDK4, and VEGFR.11,12,17 In addition, 
MRS expression is increased in lung cancer tissues, compared 
with adjacent, normal-appearing lung tissues, and its overex-
pression is associated with poor clinical outcomes in lung 
cancer patients.14 Therefore, MRS is considered to be a candi-
date for biomarker diagnosis of lung cancer. Therefore, we in-
vestigated the usefulness of MRS as a biomarker for diagnos-
ing LN metastasis in NSCLC by evaluating its expression in 
cytology specimens obtained from the EBUS-TBNA procedure.
MATERIALS AND METHODS
Antibodies, cells, and other materials 
Anti-MRS antibodies [EPR9873(B)] were obtained from On-
cotag (HFTAG201, Suwon, Korea), while the anti-CD3 (2GV6) 
rabbit monoclonal primary antibody was obtained from Ven-
tana Inc. (790-4341, Arizona, AZ, USA), the NovocastraTM Liquid 
Mouse monoclonal antibody CD20 from Leica (NCL-L-CD20-
L26, Newcastle, UK), the CD14 (5A3B11B5) mouse antibody 
(sc-58951, Dallas, TX, USA) from Santa Cruz Biotechnology, 
the human CD45 mouse antibody (MAB1430, Minneapolis, 
MN, USA) from R&D systems, and the thyroid transcription 
factor-1 (SPT24) mouse antibody (PA0364, Newcastle, UK) 
from Leica Biosystems. The anti-Mouse-AF555 (4409), and 
anti-rabbit-AF (4412) antibodies were obtained from Cell Sig-
naling Technology (Danvers, MA, USA). Molt-4, Daudi, and 
H460 cells were obtained from the Korean Cell Line Bank 
(Seoul, Korea). ThinPrep PreservCyt® Solution was obtained 
from Hologic Inc. (#70097-002, Marlborough, MA, USA) and 
the Envision Kit and DAB from Dako (#K3468, Carpinteria, 
CA, USA).
Study subjects and sample collection
Study samples were prospectively obtained from patients who 
1) visited Severance or Gangnam Severance Hospital, affiliated 
with Yonsei University, 2) were suspected to have lung cancer, 
3) agreed to undergo EBUS-TBNA, 4) had significant LN en-
largement (greater than 1.0 cm in short diameter) on enhanced 
CT, and 5) provided consent for the use of specimens. After
completion of routine cytologic examination and evaluation
of the cellular aspirates from EBUS-TBNA by the pathology
department, residual cells were mounted on slides using the
ThinPrep (Hologic Inc.) procedure and stained. This study
was approved by the institutional review board (IRB) of Gang-
nam Severance Hospital (IRB #4-2017-0387) and was carried
out in compliance with the Declaration of Helsinki and Korean 
good clinical practice guidelines. 
Immunohistochemistry (IHC)
Sections mounted on the slides were immersed three times 
for 5 minutes in xylene, two times for 2 minutes in 100% etha-
nol, for 2 minutes in 95%, 90%, and 70% ethanol and distilled 
water, and then for 5 minutes in 1X phosphate-buffered saline 
(PBS) for deparaffinization and rehydration. After quenching 
the endogenous peroxidase activity by treatment with 0.3% 
hydrogen peroxide for 10 minutes, the antigen was retrieved 
through immersion in preheated 0.1 M citrate buffer (pH 6.0) 
1007
Jung Mo Lee, et al.
https://doi.org/10.3349/ymj.2019.60.11.1005
and then boiling for 5 minutes three times at 30-second inter-
vals. The sections were then washed with 1X PBS-T (0.3% 
Tween-20) and blocked with blocking solution containing 2% 
goat serum and 2% bovine serum albumin in PBS for 30 min-
utes at 4°C. The primary antibody was diluted with the block-
ing solution and incubated with the sections at 4°C overnight. 
The dilution factors of the primary antibodies were as follows: 
MRS, 1:250; CD3 antibody working solution and CD20, 1:100; 
thyroid transcription factor 1, CD14, and CD45, 1:200. The next 
day, sections were treated with an Envision+ System-HRP-la-
belled polymer anti-rabbit/mouse solution (K5007, Dako, Car-
pinteria, CA, USA) at 4°C for 1 hour and visualized with DAB 
chromogen (NovocastraTM). After immersion in Mayer's hema-
toxylin solution for 1 minute, the sections were washed, dehy-
drated, and mounted with coverslips. 
Immunofluorescence (IF) staining
ThinPrep slides (Hologic Inc.) were immersed in 1X PBS for 5 
minutes and then permeabilized with 0.2% PBS-T at room 
temperature for 30 minutes. After washing with 1X PBS, sec-
tions were blocked with 2% goat serum for 1 hour and then 
incubated with the primary antibody mixture, wherein MRS 
was diluted at a ratio of 1:250 and CD45 at a ratio of 1:100 in 
PBS, for 90 min. After washing, sections were incubated with a 
1:1000 diluted secondary antibody mixture containing anti-
Rabbit-AF488 and anti-Mouse-AF555 at room temperature for 
1 hour and then reacted with 4'6-diamidino-2-phenylindole for 
1 minute to counterstain the nucleus. Slides were mounted with 
coverslips using ProLong Gold Antifade Reagent® (P36930, In-
vitrogen, Carlsbad, CA, USA) and slides were shaded and stored 
frozen at -20°C. Stained slides were observed using a Carl-Zeiss 
Imager M2 fluorescence microscope (Imager M2, Carl Zeiss, 
Oberkochen, Germany) and a Carl-Zeiss LSM 750 confocal 
microscope (Carl Zeiss), and images were analyzed using ZEN-
lite software (Carl-Zeiss).
Interpretation criteria and statistical analysis
The following four criteria were applied for the classification 
of cells as NSCLC: 1) a nucleus diameter ≥10 μm, 2) no inden-
tation in the nucleus, 3) prominent nucleoli, and 4) MRS posi-
tivity and CD45 negativity. The MRS and CD45 staining results 
of clinical specimens were interpreted by comparing the 
staining intensity of the reference sample, which comprised a 
1:1:1 mixture of H460 NSCLC cells, Molt-4 T-cell lymphoblas-
tic cells, and Daudi B lymphoblastic cells. MRS was expressed 
in all cells in the reference sample, and clinical specimens 
were deemed positive when stained with the same or higher 
intensity than the reference. CD45 was expressed in two thirds 
of the cells in the reference sample, except H460 cells, and 
clinical specimens were deemed positive when staining in-
tensity was the same or higher than that of the reference sam-
ple. Two independent researchers (A Kim and JM Lee) who 
were blinded to the pathological reports read the slides, and in 
case of discrepancy between the results of these two investiga-
tors, a third researcher (YS Chang) also evaluated the slides. 
The sensitivity and specificity of MRS/CD45 IF staining, con-
ventional cytology test, and PET-CT were compared with the 
those of EBUS-TBNA core biopsies, a gold standard.
RESULTS
MRS strongly expressed in NSCLC cells metastasized 
to the LNs
Previous studies have shown that MRS is overexpressed in 
about 77.4% of NSCLC tissues.14 To investigate whether these 
findings were also observable in NSCLC cells metastasized to 
the LNs, MRS IHC staining was performed in five LN surgical 
specimens that were confirmed to harbor NSCLC cell metas-
tasis. In all five samples, MRS was clearly overexpressed in the 
cancer cell cytoplasm, compared to non-malignant cells com-
prising LN structures (Fig. 1). Meanwhile, however, weak MRS 
expression was detected in cells other than NSCLC cells in the 
LNs.
CD45 as a useful biomarker for differentiating other 
lymphoid structures expressing NSCLC and MRS
In order to develop a method for distinguishing MRS-express-
ing LN constructs from NSCLC cells in LNs, additional IHC 
staining was performed using biomarkers for the cells consti-
tuting the lymphoid system (Fig. 2). Because the periphery of 
germinal centers that showed weak MRS expression was 
matched with the region where mature B-cells are primarily 
found, IHC staining for CD20, a B-lymphocyte marker, was 
carried out. Interestingly, areas that were weakly positive for 
MRS well corresponded with CD20-positive areas. To clarify 
whether CD20-positive B lymphocytes were the only cells ex-
pressing MRS, further IHC studies were performed using thy-
mic tissues, where T-cells are abundant, obtained during the 
operation of thymoma and B-cell enriched splenic tissues. In 
these tissues, the expression of MRS corresponded with that of 
CD20; however, a few cells weakly expressing MRS were also 
observed in the deep paracortical area and trabeculae where 
T-lymphocytes and macrophages/monocytes are present. Ad-
ditional IHC staining for MRS, CD3, CD14, and CD20 was per-
formed in tonsil tissue, which is structurally similar to lymphoid 
systems in the LN. Similar to the results seen in the LN, splen-
ic, and thymic tissues, MRS expression and CD20 expression 
were most often co-localized, although co-localization with 
MRS was also more rarely observed in CD3- and CD14-ex-
pressing cells. This suggests that CD20 expression alone could 
not differentiate LN cells expressing MRS nor NSCLC cells. 
Therefore, IHC staining was performed using the leukocyte 
common antigen marker CD45, and the results showed that 
MRS expression in areas other than in NSCLC cells was well 
co-localized with CD45-positive areas. 
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Fig. 1. Hematoxylin and eosin stain (A) and methionyl-tRNA synthetase immunohistochemistry (B and C) staining of three lymph node specimens of 
non-small cell lung cancer metastasis. Each column represents the same case (A and B: ×100, C: ×400). Representative cases are shown. 
Fig. 2. Immunohistochemistry for methionyl-tRNA synthetase (MRS), CD20 (B-lymphocytes), CD3 (T-lymphocytes), CD14 (macrophages and mono-
cytes), and CD45 (leukocyte common antigen) markers in the lymph nodes with non-small cell lung cancer, splenic tissue, thymic tissue from the thy-
moma, and tonsils. Magnification: ×100.
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Preparation of reference specimens using MRS- and 
CD45-expressing cells
We hypothesized that MRS and CD45 double staining would 
be appropriate for confirming the presence of LN metastasis 
of NSCLC. MRS and CD45 double stained cells are leukocyte 
lineage cells, and MRS positive and CD45 negative cells were 
judged to be NSCLC cells, which was established as one of the 
major criteria for judging NSCLC cells, in addition to nucleus 
size, shape, and nucleoli characteristics, as described in the 
materials and methods section. To apply these findings to the 
interpretation of cytologic samples obtained from EBUS-TB-
NA, a 1:1:1 mixture of H460, Daudi, and Molt-4 cells was pro-
cessed as described previously, and ThinPrep® slides (Hologic 
Inc.) of this mixture were prepared and used as a reference 
sample for IHC and IF staining of clinical specimens (Fig. 3A). 
When the reference samples were stained for MRS and CD45, 
the ratio of MRS positive to MRS/CD45 double positive cells 
was 1:2. When studying the clinical specimens, reference 
samples were stained simultaneously and used for qualitative 
interpretation of cell staining in the cytological specimens (Fig. 
3B and C).
Application of MRS/CD45 dual IF staining to clinical 
specimens
EBUS-TBNA was performed for 138 LNs from 108 patients (Ta-
ble 1). Among the 138 LNs biopsied, lung cancer metastasis 
was confirmed in 74 cases (53.6%), and no evidence of cancer 
was found in 64 cases (46.4%). Among the cases with cancer 
metastasis, adenocarcinoma was the most common (71.6%), 
followed by squamous cell carcinoma (25.7%) and others (2.7%). 
The locations of the LNs where EBUS-TBNA was performed 
were the subcarinal LNs in 54 (39.1%) cases, paratracheal LNs 
in 52 (37.7%) cases, and hilar or interlobar LNs in 32 (23.2%) 
cases. Representative IF images of MRS and CD45 from EBUS-
TBNA cytologic specimens are shown in Fig. 3D and E. Using 
EBUS-TBNA core tissue biopsy results as a reference, the re-
sults of MRS/CD45 IF staining were compared with those of 
conventional cytology test and PET-CT imaging. The sensitivi-
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Fig. 3. Immunoblotting of methionyl-tRNA synthetase (MRS)-positive H460 cells, CD45/CD3-positive Molt-4 cells, and CD45/CD20-positive Daudi cells 
(A). Fluorescent immunochemical staining for MRS and CD45 in the reference samples containing a fixed ratio of H460, Daudi, and Molt-4 cells (B and 
C) and endobronchial ultrasound-guided transbronchial needle aspirate-derived samples (D and E). Images were taken using a fluorescent micro-
scope (B and D) and confocal microscope (C and E). Blue represents nucleus (4', 6-Diamidine-2'-phenylindole dihydrochloride: DAPI); green, MRS; and 
red, CD45. B and D confocal images show merged images only. TTF-1, thyroid transcription factor 1.
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ty of MRS/CD45 IF staining was 76.7%, and the specificity was 
90.8%. In contrast, those for conventional cytology were 71.8% 
and 100.0%, respectively. PET-CT imaging showed a sensitivi-
ty and specificity of 88.4% and 63.0%, respectively. Combining 
the results of MRS/CD45 IF staining with that of conventional 
cytology test increased sensitivity and specificity to 87.3% and 
91.9%, respectively. When combining the results of cytology 
and PET-CT, which is commonly applied in medical practice, 
the sensitivity and specificity were 71.6% and 100%, respec-
tively, and the addition of MRS/CD45 IF to these results result-
ed in a sensitivity and specificity of 85.1% and 97.8%, respec-
tively (Tables 2 and 3, Fig. 4). Taken together, while MRS/CD45 
IF staining was more sensitive than conventional cytology, the 
specificity was lower; meanwhile, in comparison with PET-CT 
imaging, the sensitivity of MRS/CD45 IF staining was lower, 
but its specificity was higher.
DISCUSSION
Accurate mediastinal LN staging is important for disease stag-
ing and the selection of appropriate treatment modalities in 
lung cancer patients.18 In the EBUS-TBNA procedure, the diag-
nostic yield increases when a core tissue specimen is secured, 
whereas when only cytology specimens are obtained, the di-
agnosis rate decreases. Approximately 15 to 20% of LN aspi-
rates result in non-diagnostic quality specimens.19,20 In addi-
tion, a lot of time and labor are required to obtain a core tissue 
biopsy specimen, and the rate of complications increases ac-
cordingly. Since EBUS-TBNA is an invasive and costly test, it is 
necessary to develop an accurate diagnostic method using cyto-
logic specimens. Here, surplus cytologic specimens were pro-
spectively collected from patients who underwent EBUS-TBNA 
under the suspicion of LN metastasis of lung cancer and were 
used to explore the possibility of MRS as a biomarker of LN 
metastasis in lung cancer. 
ARSs are housekeeping enzymes that catalyze the ligation of 
amino acids to their cognate tRNAs with high fidelity.11 Based 
on the roles of ARSs, their overexpression is expected to affect 
the growth and progression of cancer, which has an increased 
metabolic activity. Among them, MRS is a major enzyme in 
the initiation of ARS protein synthesis, transferring a Met to the 
initiator tRNA (tRNAiMet). Dysfunctions of MRS have been ob-
served in interstitial lung disease, Charcot–Marie–Tooth dis-
ease, and pulmonary alveolar proteinosis.21,22 
Previously, our group observed overexpression of MRS in 
mouse lung cancer models and human tissue obtained through 
surgery, and confirmed that this overexpression was associat-
ed with a poor prognosis in NSCLC patients.14 In this study, 
we confirmed the possibility of MRS as a biomarker for lung 
cancer by confirming its expression in aspirated cell speci-
mens, which can be secured safely from EBUS-TBNA. To date, 
the relationship between MRS and LN metastasis is, as of yet, 
unknown, although we suspect that it may affect cancer pro-
gression by increasing cell turnover. Based on the expression 
patterns of MRS in these needle aspirate cytology specimens, 
its usage as a biomarker might be able to be extended to other 
cytology specimens, such as pleural effusion and bronchoal-
veolar lavage specimens, to aid in the diagnosis of lung cancer.
MRS overexpression was mainly observed in lung cancer 
Table 1. Demographic Characteristics of the Study Cases
Baseline characteristics Values
No. of patients 108
Age (yr) (range)      69.0 (61.0–6.0)
Men (n, %) 68 (63.0)
Serum CEA level (ng/mL) (range)       3.5 (1.9–10.6)
No. of LNs 138
Location of LNs (n, %)
Paratracheal LN 52 (37.7)
Subcarinal LN 54 (39.1)
Hilar, interlobar LN 32 (23.2)
Core pathology (n, %)
No evidence of cancer 64 (46.4)
Adenocarcinoma 53 (38.4)
Squamous cell carcinoma 19 (13.8)
Poorly differentiated carcinoma 2 (1.4)
CEA, carcinoembryonic antigen; LN, lymph node.
Values are presented as median (range) or n (%) unless otherwise indicated.
Table 3. Comparison of Diagnostic Yields
Sensitivity 
(%)
Specificity 
(%)
AUC
MRS/CD45 IF staining 76.7   90.8 0.837
Cytology 71.8 100.0 0.859
PET-CT 88.4   63.0 0.747
Cytology+PET-CT 71.6 100.0 0.925
Cytology+PET+MRS/CD45 IF staining 85.1   97.8 0.952
AUC, area under the curve; MRS, methionyl-tRNA synthetase; IF, immunoflu-
orescent; PET-CT, positron emission tomography-computed tomography.
Table 2. Comparison of Results
Core pathologic results
MRS IF staining Conventional cytology* PET-CT†
Positive Negative Positive Negative Positive Negative
Malignant lesion 56 17 51 20 61   8
Benign lesion   6 59   0 62 17 29
MRS, methionyl-tRNA synthetase; IF, immunofluorescent; PET-CT, positron emission tomography-computed tomography.
*Cytologic results for five lesions were not available; †PET-CT of 23 lesions was not available.
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cells, although weak expression was observed in other cells 
comprising the LN, suggesting that there is a limit to the use of 
MRS alone as a diagnostic biomarker. Additional markers were 
developed to complement this, and we confirmed that double 
staining with CD45 can complement false positive results of 
MRS in non-cancer cells. Using various lymphoid tissues, such 
as those from the spleen, thymoma, and tonsils, we found that 
the majority of cells that express MRS were CD20-positive B-
cells. Considering the role of CD20-positive B-cell synthesiz-
ing immunoglobulins, MRS positivity in that subset of lym-
phoid cells is predictable. T-cells and other immune system cells 
also showed intermittent expression of MRS, which would be 
expected in a metabolically active state.
MRS and CD45 double IF staining showed specificity for lung 
cancer cells on thin-prep specimens from EBUS-TBNA proce-
dures, and the results showed higher sensitivity than those of 
conventional cytological examination, suggesting that MRS/
CD45 staining could be a good candidate as a complementary 
diagnostic tool for the detection of LN metastasis in lung can-
cer. Occasionally, the EBUS-TBNA method does not procure 
the appropriate core tissue specimen and acquires only the 
cell specimen. In this case, this method could be applied as 
an assistant method for diagnosis. In medical practice, it is not 
uncommon for cases in which an initial routine examination 
reports a non-malignancy that is confirmed as lung cancer 
later. For example, in this study, a case with a negative result 
of EBUS-TBNA cytology test and core biopsy showed mild to 
moderately increased uptake at right lower paratracheal LN in 
PET-CT. However, this patient had positive MRS/CD45 IF 
staining, and the final histopathologic diagnosis was squa-
mous cell carcinoma (Supplementary Fig. 1, only online). In 
addition, this method could be applied as a basis for the de-
velopment of ROSE to determine the suitability of EBUS-de-
rived cytological specimens.23 
Considering that these results were obtained from residual 
specimens that were used and left after for routine cytopa-
thology studies, better diagnostic yield might be expected if 
appropriate samples are used in the future. Along with CD45/
MRS dual staining positivity, a nuclear diameter of more than 
10 μm and the presence of nucleoli were included in our diag-
nostic criteria. This suggests that a small proportion of small 
cell lung cancer cells, the nuclear diameter of which is 9.2±2.1 
μm, might be of use, along with CD45/MRS dual staining.24 In 
addition, CD45-negativity has been observed in Reed-Stern-
berg cells and their variants, as well as some anaplastic large 
cell lymphomas.25 This indicates the need for careful inspec-
tion of the nucleus, including the presence of nucleoli, as well as 
complementary studies, such as radiologic findings and clinical 
manifestations, in cases where a homogenous population of 
MRS-positive and CD45-negative cells is observed.
In order to detect metastasis of NSCLC to LNs, a patholo-
gist’s experience is critical. To improve diagnostic yield when 
only a small number of cells is available, MRS/CD45 dual IF 
staining may be a good complementary test.
In conclusion, double IF staining for MRS and CD45 showed 
promising diagnostic performance and may be of use as a 
complementary test to conventional cytological tests in order 
to determine metastasis of lung cancer to the LNs when only 
limited cytologic specimen is available.
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s.e., standard error; est., estimates.
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